Ascendis Pharma AS (ASND) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ascendis Pharma AS (ASND) has a cash flow conversion efficiency ratio of -0.016x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.85 Million) by net assets ($488.48 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ASND net asset quality score to measure how much of total assets are equity-financed.
Ascendis Pharma AS - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Ascendis Pharma AS's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Ascendis Pharma AS (ASND) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Ascendis Pharma AS Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ascendis Pharma AS ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Capgemini SE
PA:CAP
|
0.183x |
|
WUXI BIOLOGICS UNSP.ADR/2
F:1FW1
|
N/A |
|
Bharat Petroleum Corporation Limited
NSE:BPCL
|
0.227x |
|
Zhejiang Century Huatong Group Co Ltd
SHE:002602
|
0.079x |
|
H.K. CHINA GAS HD-25 ADR
F:HCGS
|
N/A |
|
Zhongjin Gold Corp Ltd
SHG:600489
|
0.035x |
|
Suncorp Group Ltd
AU:SUN
|
0.036x |
|
Grupo Financiero Inbursa S.A.B. de C.V
MX:GFINBURO
|
-0.072x |
Annual Cash Flow Conversion Efficiency for Ascendis Pharma AS (2012–2025)
The table below shows the annual cash flow conversion efficiency of Ascendis Pharma AS from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see Ascendis Pharma AS stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-162.75 Million | $51.77 Million | -0.318x | -110.98% |
| 2024-12-31 | $-105.71 Million | $-306.20 Million | 2.897x | -9.70% |
| 2023-12-31 | $-145.70 Million | $-467.36 Million | 3.208x | +270.42% |
| 2022-12-31 | $263.35 Million | $-495.70 Million | -1.882x | -298.24% |
| 2021-12-31 | $883.63 Million | $-417.65 Million | -0.473x | -45.98% |
| 2020-12-31 | $838.71 Million | $-271.55 Million | -0.324x | -9.88% |
| 2019-12-31 | $597.11 Million | $-175.94 Million | -0.295x | +40.55% |
| 2018-12-31 | $280.05 Million | $-138.80 Million | -0.496x | +2.43% |
| 2017-12-31 | $187.21 Million | $-95.10 Million | -0.508x | -49.08% |
| 2016-12-31 | $176.61 Million | $-60.18 Million | -0.341x | +5.67% |
| 2015-12-31 | $120.33 Million | $-43.47 Million | -0.361x | +10.08% |
| 2014-12-31 | $45.81 Million | $-18.40 Million | -0.402x | -140.12% |
| 2013-12-31 | $6.30 Million | $6.31 Million | 1.001x | +338.99% |
| 2012-12-31 | $1.56 Million | $-652.00K | -0.419x | -- |
About Ascendis Pharma AS
Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is a… Read more